Table 1. Relationship between phospho-DICER1 (A), phospho-ERK (B), and clinicopathological features in LUADs.
LVI, lymph node invasion. There are a total of 88 samples in phospho-DICER1 staining and 87 samples in phospho-ERK staining. Sex data are missing from two cases; grade and LVI data are missing from six cases, and stage is missing from twelve cases. T4 only has one sample.
A. Clinicopathology factors | Nuclear phospho-DICER1 expression | ||||
---|---|---|---|---|---|
Negative | Low | Moderate | High | ||
N | N | N> | N | P* | |
Sex | |||||
Female | 0 | 19 | 22 | 5 | 0.6046 |
Male | 0 | 17 | 21 | 2 | |
Tumor size (T) | |||||
T1 | 0 | 9 | 13 | 4 | 0.5589 |
T2 | 0 | 19 | 19 | 2 | |
T3–T4 | 0 | 6 | 9 | 1 | |
Stage | |||||
I | 0 | 21 | 20 | 4 | 0.839 |
II | 0 | 8 | 11 | 2 | |
III | 0 | 5 | 5 | 0 | |
LVI | |||||
Present | 0 | 8 | 12 | 2 | 0.7012 |
Absent | 0 | 28 | 27 | 5 | |
KRAS mutations | |||||
Mutated | 0 | 9 | 25 | 4 | 0.0098 |
Not Mutated | 0 | 28 | 19 | 3 | |
B. Clinicopathology factors | Phospho-ERK expression | ||||
Negative | Low | Moderate | High | ||
N | N | N | N | P* | |
Sex | |||||
Female | 15 | 22 | 5 | 3 | |
Male | 8 | 28 | 2 | 2 | |
Tumor size (T) | |||||
T1 | 6 | 13 | 3 | 4 | 0.1888 |
T2 | 10 | 27 | 1 | 1 | |
T3–T4 | 5 | 9 | 2 | 0 | |
Stage | |||||
I | 12 | 29 | 0 | 3 | 0.676 |
II | 5 | 14 | 1 | 1 | |
III | 4 | 6 | 0 | 0 | |
LVI | |||||
Present | 5 | 13 | 3 | 2 | 0.1048 |
Absent | 16 | 38 | 2 | 2 | |
KRAS mutations | |||||
Mutated | 7 | 20 | 6 | 5 | 0.0034 |
Not mutated | 16 | 32 | 1 | 0 |
*Chi-square test.